Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Nabumetone | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Nabumetone | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Nabumetone | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Nabumetone | hsa00500 | Starch and sucrose metabolism | 5.73E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Nabumetone | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Nabumetone | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Nabumetone | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Nabumetone | hsa00730 | Thiamine metabolism | 5.35E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Nabumetone | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Nabumetone | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Nabumetone | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Nabumetone | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Nabumetone | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Nabumetone | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Nabumetone | hsa03013 | RNA transport | 3.53E-02 | 6 | P62826, Q15287, Q9UBU9, P63279, P20042, Q14232 | RAN, RNPS1, NXF1, UBE2I, EIF2S2, EIF2B1 | More | | Nabumetone | hsa03060 | Protein export | 3.20E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Nabumetone | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Nabumetone | hsa04062 | Chemokine signaling pathway | 1.83E-02 | 8 | P25024, P25025, P09341, P19875, P42338, P19174, P63218, P50151 | CXCR1, CXCR2, CXCL1, CXCL2, PIK3CB, PLCG1, GNG5, GNG10 | More | | Nabumetone | hsa04064 | NF-kappa B signaling pathway | 2.98E-04 | 13 | P10415, O00463, P14778, P19174, Q04759, Q9UDY8, Q16548, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, TRAF5, IL1R1, PLCG1, PRKCQ, MALT1, BCL2A1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Nabumetone | hsa04071 | Sphingolipid signaling pathway | 2.60E-05 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | | Nabumetone | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Nabumetone | hsa04080 | Neuroactive ligand-receptor interaction | 6.04E-04 | 8 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | Nabumetone | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Nabumetone | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Nabumetone | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Nabumetone | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Nabumetone | hsa04210 | Apoptosis | 4.11E-03 | 9 | Q13315, P10415, O76075, P01375, Q9NR28, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, TNF, DIABLO, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Nabumetone | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Nabumetone | hsa04217 | Necroptosis | 1.85E-02 | 6 | P23458, Q9NQC7, P01584, P0C0S5, Q9H444, O75351 | JAK1, CYLD, IL1B, H2AFZ, CHMP4B, VPS4B | More | | Nabumetone | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Nabumetone | hsa04340 | Hedgehog signaling pathway | 2.61E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Nabumetone | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Nabumetone | hsa04380 | Osteoclast differentiation | 4.17E-02 | 4 | Q9NQC7, Q9UQC2, P23458, P01584 | CYLD, GAB2, JAK1, IL1B | More | | Nabumetone | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Nabumetone | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Nabumetone | hsa04612 | Antigen processing and presentation | 2.58E-04 | 7 | P13765, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Nabumetone | hsa04613 | Neutrophil extracellular trap formation | 3.77E-03 | 12 | O60603, P05164, P08246, Q9UM07, Q93077, P62807, O60814, P68431, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, C5AR1 | More | | Nabumetone | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Nabumetone | hsa04650 | Natural killer cell mediated cytotoxicity | 1.11E-08 | 17 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.718 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.764 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.869 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.863 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.803 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.762 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.853 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.853 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Nabumetone | hsa04657 | IL-17 signaling pathway | 2.10E-03 | 5 | P49841, P19875, P14780, P80188, P01375 | GSK3B, CXCL2, MMP9, LCN2, TNF | More | | Nabumetone | hsa04658 | Th1 and Th2 cell differentiation | 3.29E-08 | 13 | Q04759, P07766, P20963, P09693, Q16539, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Nabumetone | hsa04659 | Th17 cell differentiation | 2.21E-06 | 12 | Q04759, Q16539, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Nabumetone | hsa04660 | T cell receptor signaling pathway | 1.09E-04 | 12 | Q9UDY8, Q04759, P42338, P10747, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | MALT1, PRKCQ, PIK3CB, CD28, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Nabumetone | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Nabumetone | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Nabumetone | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Nabumetone | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Nabumetone | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Nabumetone | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Nabumetone | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Nabumetone | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Nabumetone | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Nabumetone | hsa04924 | Renin secretion | 8.77E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Nabumetone | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Nabumetone | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Nabumetone | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | | Nabumetone | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Nabumetone | hsa04932 | Non-alcoholic fatty liver disease | 2.78E-02 | 5 | O43521, O75460, P01584, P12074, O95298 | BCL2L11, ERN1, IL1B, COX6A1, NDUFC2 | More | | Nabumetone | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Nabumetone | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Nabumetone | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Nabumetone | hsa04971 | Gastric acid secretion | 4.51E-02 | 3 | Q08828, P15311, P0DP23 | ADCY1, VIL2, CALM1 | More | | Nabumetone | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Nabumetone | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Nabumetone | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Nabumetone | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Nabumetone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Nabumetone | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Nabumetone | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Nabumetone | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Nabumetone | hsa05144 | Malaria | 7.08E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Nabumetone | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | Nabumetone | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Nabumetone | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Nabumetone | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Nabumetone | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | | Nabumetone | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Nabumetone | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Nabumetone | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Nabumetone | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Nabumetone | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Nabumetone | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.73E-05 | 10 | P42338, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14 | More | | Nabumetone | hsa05321 | Inflammatory bowel disease | 6.21E-05 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Nabumetone | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Nabumetone | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Nabumetone | hsa05332 | Graft-versus-host disease | 7.32E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Nabumetone | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |